Head and Neck Cancer

Combination of therapies halt squamous cell carcinoma

Published in Gene Therapy Weekly, December 19th, 2002

by Sonia Nichols, senior medical writer - Therapeutic strategies encompassing gene therapy and antiangiogenesis agents may be useful for human head and neck squamous cell carcinoma (HNSCC).

Mengfen Li and colleagues, University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, reported using such a combination to combat HNSCC in both nude and immunocompetent mice.

According to Li and coauthors, the combination therapy included endostatin, a natural angiogenesis inhibitor, and epidermal growth factor receptor antisense gene therapy administered in liposomes. The researchers segregated mice into four groups and delegated them to receive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry